Vale Dr Susan Foden, Non-executive Chair
BRISBANE, 5 November 2024
It is with profound sadness that QBiotics Group Limited (QBiotics) announces the passing of Dr Susan Foden, Non-Executive Chair. The Board extends its deepest sympathies and condolences to Sue’s family, friends and colleagues.
Sue was appointed as a director of QBiotics Group on 14 October 2019 and held a key role as a member of the Remuneration Committee, including as its Chair for a period of time. She served as Executive Chair through 2023 and 2024, with her oversight instrumental for preserving the Company’s momentum and stability during a leadership transition period.
QBiotics’ CEO and Managing Director, Stephen Doyle commented, “Sue was an integral part of our company, guiding us with her strong leadership, commitment to excellence and tireless dedication. Her contributions to QBiotics and to the industry as a whole have been immeasurable, and her loss will be deeply felt by all who had the privilege of knowing and working with her. Our thoughts and condolences are with Sue’s family. She will be sadly missed.”
The Board is in the process of determining the next Chair for QBiotics. A further announcement will be made in due course.
—ends—
FURTHER INFORMATION
STEPHEN DOYLE, CEO & MANAGING DIRECTOR
communications@qbiotics.com or
MEDIA ENQUIRIES / NOTES FOR EDITORS
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au +61 411 117 774
ABOUT QBIOTICS
QBiotics is an unlisted public Australian life sciences company that specialises in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.
QBiotics’ lead oncology drug, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.
QBiotics’ lead wound healing drug candidate, EBC 1013 is a small molecule targeting a range of wounds including chronic and acute wounds and burns. A first-in-human Phase I clinical development in patients with venous leg ulcers is open for recruitment.